Atara Biotherapeutics Inc Stock Research

Market Summary

USD2.97+0.10

Market Closed

3.48%

ATRA Stock Price

ATRA RSI Chart

ATRA Valuation

Market Cap

284.9M

Price/Earnings (Trailing)

-1.25

Price/Sales (Trailing)

4.48

EV/EBITDA

-0.86

Price/Free Cashflow

-1.04

ATRA Price/Sales (Trailing)

ATRA Profitability

EBT Margin

-359.10%

Return on Equity

-180.28%

Return on Assets

-60.65%

Free Cashflow Yield

-96.39%

ATRA Fundamentals

ATRA Revenue

Revenue (TTM)

63.6M

Revenue Y/Y

-97.07%

Revenue Q/Q

-99.15%

ATRA Earnings

Earnings (TTM)

-228.3M

Earnings Y/Y

20.11%

Earnings Q/Q

11.32%

Price Action

52 Week Range

2.6610.01

(Low)(High)

Last 7 days

-0.3%

Last 30 days

-26.8%

Last 90 days

4.2%

Trailing 12 Months

-68.4%

ATRA Financial Health

Current Ratio

3.74

ATRA Investor Care

Shares Dilution (1Y)

4.64%

Diluted EPS (TTM)

-2.24

Peers (Alternatives to Atara Biotherapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	126.4B	26.3B	1.33%	2.31%	19.3	4.8	1.32%	11.18%
GILD	99.2B	27.3B	-0.40%	40.80%	21.61	3.64	-0.09%	-26.23%
MRNA	57.1B	19.3B	6.53%	-10.59%	6.83	2.96	4.29%	-31.47%
BIIB	39.0B	10.2B	-0.01%	27.97%	12.8	3.83	-7.36%	95.80%
MID-CAP
NBIX	9.4B	1.5B	-5.27%	3.55%	60.62	6.29	31.34%	72.43%
DNLI	3.2B	108.5M	-10.19%	-29.91%	-9.71	29.17	122.90%	-12.19%
BEAM	2.2B	60.9M	-21.53%	-47.37%	-7.53	35.73	17.51%	22.00%
BBIO	2.2B	107.9M	22.92%	38.22%	-4.45	19.98	54.84%	17.36%
SMALL-CAP
RCUS	1.3B	112.0M	-3.60%	-50.92%	-4.82	11.49	-70.76%	-603.77%
REPL	1.1B	7.0M	-2.83%	20.33%	-6.95	155.42	131.81%	-45.39%
FATE	533.2M	96.3M	-5.35%	-85.58%	-1.89	5.54	72.44%	-32.79%
NVAX	524.0M	2.0B	-30.95%	-91.78%	-0.8	0.26	72.89%	62.27%
SGMO	290.2M	111.3M	-34.46%	-69.74%	-1.51	2.61	0.54%	-7.86%
VXRT	102.0M	107.0K	-5.82%	-84.77%	-0.95	953.19	-88.00%	-52.91%
IBIO	30.1M	-	102.50%	-80.56%	-0.37	3.21	0.51%	-185.61%

Financials for Atara Biotherapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-6.1%	63,573,000	67,692,000	71,811,000	24,102,000	20,340,000
Operating Expenses	-6.8%	344,086,000	369,277,000	370,378,000	374,539,000	360,802,000
S&GA Expenses	-10.7%	71,553,000	80,125,000	81,050,000	81,634,000	78,801,000
R&D Expenses	-5.7%	272,533,000	289,152,000	289,328,000	292,905,000	282,001,000
EBITDA	7.4%	-222,302,000	-239,940,000	-239,730,000	-341,150,000	-
EBITDA Margin	1.3%	-3.50	-3.54	-3.34	-14.15	-
Earnings Before Taxes	7.6%	-228,290,000	-247,039,000	-247,622,000	-349,865,000	-340,095,000
EBT Margin	1.6%	-3.59	-3.65	-3.45	-14.52	-
Interest Expenses	27.4%	335,000	263,000	147,000	27,000	32,000
Net Income	7.6%	-228,302,000	-247,079,000	-247,652,000	-349,911,000	-340,141,000
Net Income Margin	1.6%	-3.59	-3.65	-3.45	-14.52	-
Free Cahsflow	-7.9%	-274,623,000	-254,441,000	-252,086,000	-250,341,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	2.2%	376	368	436	397	468
Current Assets	4.3%	295	283	347	314	385
Cash Equivalents	42.7%	93.00	65.00	71.00	102	106
Inventory	Infinity%	2.00	-	-	-	-
Net PPE	-13.3%	6.00	7.00	8.00	9.00	54.00
Liabilities	37.8%	250	181	179	173	189
Current Liabilities	9.2%	79.00	72.00	66.00	102	106
Shareholder's Equity	-32.3%	127	187	257	224	280
Retained Earnings	-4.6%	-1,693	-1,618	-1,534	-1,552	-1,464
Additional Paid-In Capital	0.7%	1,822	1,809	1,794	1,779	1,745
Accumulated Depreciation	9.7%	12.00	11.00	10.00	29.00	-
Shares Outstanding	1.1%	96.00	95.00	94.00	93.00	92.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-9.1%	-270	-247	-241	-239	-220
Share Based Compensation	-4.7%	54.00	57.00	56.00	56.00	54.00
Cashflow From Investing	59.3%	203	127	69.00	69.00	22.00
Cashflow From Financing	-26.5%	53.00	72.00	120	121	104

Risks for ATRA

What is the probability of a big loss on ATRA?

100%

Probability that Atara Biotherapeutics stock will be more than 20% underwater in next one year

89.6%

Probability that Atara Biotherapeutics stock will be more than 30% underwater in next one year.

79.2%

Probability that Atara Biotherapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ATRA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Atara Biotherapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ATRA

Cumulative Returns on ATRA

-22.1%

7-Year Cumulative Returns

-39.9%

5-Year Cumulative Returns

-29.4%

3-Year Cumulative Returns

What are the long-term rolling returns for ATRA?

FIve years rolling returns for Atara Biotherapeutics.

Annualized Returns

Which funds bought or sold ATRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-23	MetLife Investment Management, LLC	reduced	-23.72	-60,437	118,319	-%
2023-03-17	American Portfolios Advisors	reduced	-49.15	-51,932	17,010	-%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-0.04	-5,278	33,722	-%
2023-03-06	Rockefeller Capital Management L.P.	unchanged	-	-27,000	176,000	-%
2023-02-28	Voya Investment Management LLC	added	95.14	92,812	226,812	-%
2023-02-21	MACQUARIE GROUP LTD	sold off	-	-2,000	-	-%
2023-02-16	MAVERICK CAPITAL LTD	reduced	-19.92	-9,060,480	20,634,500	0.49%
2023-02-16	JOSH ARNOLD INVESTMENT CONSULTANT, LLC	added	73.33	58,000	171,000	0.25%
2023-02-15	JANE STREET GROUP, LLC	added	89.96	190,463	485,463	-%
2023-02-15	ALLIANCEBERNSTEIN L.P.	added	11.77	-12,581	392,419	-%

Latest Funds Activity

Are funds buying ATRA calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ATRA

No. of Funds

Atara Biotherapeutics News

Schedule 13G FIlings of Atara Biotherapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	maverick capital ltd	6.6%	6,291,013	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 14, 2023	redmile group, llc	9.9%	9,837,493	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	7.60%	7,211,048	SC 13G/A
Feb 08, 2023	wasatch advisors inc	-	0	SC 13G
Feb 07, 2023	goldman sachs group inc	6.4%	6,108,260	SC 13G
Feb 03, 2023	state street corp	8.06%	7,649,740	SC 13G
Jan 24, 2023	blackrock inc.	9.6%	9,152,149	SC 13G/A
Jan 18, 2023	jpmorgan chase & co	7.9%	7,510,572	SC 13G/A

ATRA Fair Value

Recent SEC filings of Atara Biotherapeutics

View All Filings

Date Filed	Form Type	Document
Mar 24, 2023	PRE 14A	PRE 14A
Mar 10, 2023	8-K	Current Report
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading

Latest Insider Trading transactions for ATRA

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-02	Dupont Jakob	sold	-18,403	3.627	-5,074	evp, head of r&d
2023-03-02	Murugan Amar	sold	-15,309	3.627	-4,221	svp, gc & secretary
2023-03-02	Koppikar Utpal	sold	-24,921	3.627	-6,871	chief financial officer
2023-03-02	Touchon Pascal	sold	-56,867	3.627	-15,679	president and ceo
2023-03-01	Dupont Jakob	acquired	-	-	141,328	evp, head of r&d
2023-03-01	Banard Charlene A.	acquired	-	-	139,700	evp, chief technical officer
2023-03-01	Touchon Pascal	acquired	-	-	324,711	president and ceo
2023-03-01	Murugan Amar	acquired	-	-	155,375	svp, gc & secretary
2023-02-07	Koppikar Utpal	sold	-13,568	5.46	-2,485	chief financial officer
2022-11-16	Koppikar Utpal	sold	-28,086	4.49017	-6,255	chief financial officer

About Atara Biotherapeutics

Pascal Touchon

www.atarabio.com

580

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

ATRA Income Statement

2022-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
License and collaboration revenue	$ 4,459	$ 5,370	$ 63,352	$ 12,792
Operating expenses:
Research and development	70,157	70,333	210,018	202,867
General and administrative	18,924	19,849	58,308	56,984
Total operating expenses	89,081	90,182	268,326	259,851
Loss from operations	(84,622)	(84,812)	(204,974)	(247,059)
Gain on sale of ATOM Facility (See Note 7)	0	0	50,237	0
Interest and other income (expense), net	541	148	1,017	283
Total other income (expense), net, Total	541	148	51,254	283
Loss before provision for income taxes	(84,081)	(84,664)	(153,720)	(246,776)
Provision for income taxes	10	0	10	16
Net loss	(84,091)	(84,664)	(153,730)	(246,792)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities	(341)	(38)	(2,591)	(272)
Comprehensive loss	$ (84,432)	$ (84,702)	$ (156,321)	$ (247,064)
Net earnings (loss) per common share:
Basic earnings (loss) per common share	$ (0.82)	$ (0.90)	$ (1.51)	$ (2.67)
Diluted earnings (loss) per common share	$ (0.82)	$ (0.90)	$ (1.51)	$ (2.67)
Basic weighted-average shares outstanding	102,423	93,602	101,590	92,411
Diluted weighted-average shares outstanding	102,423	93,602	101,590	92,411

ATRA Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 65,114	$ 106,084
Short-term investments	200,290	264,984
Restricted cash	1,346	194
Accounts receivable	249	986
Prepaid expenses and other current assets	16,047	12,373
Total current assets	283,046	384,621
Property and equipment, net	7,270	53,780
Operating lease assets	70,834	26,159
Restricted cash - long-term	0	1,200
Other assets	7,166	2,367
Total assets	368,316	468,127
Current liabilities:
Accounts payable	11,296	17,368
Accrued compensation	17,605	25,150
Accrued research and development expenses	17,868	13,451
Deferred revenue	2,662	40,760
Other current liabilities	22,813	9,057
Total current liabilities	72,244	105,786
Deferred revenue - long-term	42,338	55,708
Operating lease liabilities - long-term	61,072	25,518
Other long-term liabilities	5,549	1,501
Total liabilities	181,203	188,513
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock - $0.0001 par value, 500,000 shares authorized as of September 30, 2022 and December 31, 2021; 94,879 and 91,671 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	9	9
Additional paid-in capital	1,808,515	1,744,695
Accumulated other comprehensive (loss) income	(2,959)	(368)
Accumulated deficit	(1,618,452)	(1,464,722)
Total stockholders’ equity	187,113	279,614
Total liabilities and stockholders’ equity	$ 368,316	$ 468,127